← Back to Search

Monoclonal Antibodies

Romosozumab + Denosumab for Osteoporosis

Phase 2

Recruiting

Led By Elizabeth Shane, MD

Research Sponsored by Columbia University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Documented adult fractures judged to be low-trauma (equivalent to a fall from a standing height or less) and T-score or Z-score ≤ -1.5 at the LS, TH or FN.

Be between 18 and 65 years old

Must not have

Any cardiovascular disease: history of myocardial infarction (MI) or stroke. Normal electrocardiogram (ECG) or ECG with no clinically significant abnormality is required at study entry.

Intestinal disorders including but not limited to celiac disease, pancreatic insufficiency, Crohn Disease or ulcerative colitis

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, 6 month, 12 month, 18 month, 24 month

Awards & highlights

Summary

This trial is testing a new osteoporosis treatment in premenopausal women to see if it is more effective than the current standard of care.

Who is the study for?

This trial is for premenopausal women aged 18-48 with idiopathic osteoporosis, regular menstrual cycles, and no secondary cause of bone loss. Participants must have had low-trauma fractures and a T-score or Z-score ≤ -1.5 at certain bone sites. They should agree to highly effective contraception during the study.Check my eligibility

What is being tested?

The study tests if romosozumab improves bone mass in premenopausal women with osteoporosis better than teriparatide does. It involves giving participants romosozumab monthly for a year followed by denosumab every six months for another year, comparing their results to historical controls.See study design

What are the potential side effects?

Possible side effects include reactions at the injection site, muscle pain, headache, joint pain, and possibly increased risk of heart problems or stroke. There's also a concern about potential harm to bones like unusual fractures.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have had fractures from minor falls and my bone density scores are low.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have a history of heart disease but my recent ECG is normal or not concerning.

Select...

I have a condition affecting my intestines, such as celiac disease or Crohn's.

Select...

I have a new, untreated hormone gland disorder.

Select...

I have a condition affecting my body's mineral levels, like vitamin D deficiency or hyperparathyroidism.

Select...

I have not had a menstrual period for over a year, not due to pregnancy or breastfeeding.

Select...

I am on long-term blood thinners.

Select...

I have been taking more than 5 mg of prednisone or similar daily for over 3 months.

Select...

I am currently taking medication to stop new blood vessels from forming in my tumor.

Select...

My kidney function is reduced (eGFR below 60).

Select...

I have cancer, but not skin cancer that's been cured.

Select...

I haven't had major dental work in the last 3 months and don't need any in the next 2 years.

Select...

My liver tests are higher than normal.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, 6 month, 12 month, 18 month, 24 month

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, 6 month, 12 month, 18 month, 24 month

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 6 month, 12 month, 18 month, 24 month for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Secondary outcome measures

Percent change in distal radius BMD by DXA

Structure of neck of femur

Percent change in lumbar spine BMD by DXA

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Romosozumab followed by denosumabExperimental Treatment2 Interventions

Romosozumab 210 mg subcutaneous injection, once a month for 12 months followed by denosumab 60 mg subcutaneous injection, once every six months for 12 months.

0 / 13Eligibility criteria met

Find a Location

Who is running the clinical trial?

Columbia UniversityLead Sponsor

1,448 Previous Clinical Trials

2,531,460 Total Patients Enrolled

AmgenIndustry Sponsor

1,392 Previous Clinical Trials

1,381,090 Total Patients Enrolled

Elizabeth Shane, MDPrincipal InvestigatorColumbia University

6 Previous Clinical Trials

354 Total Patients Enrolled

Media Library

Denosumab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT04800367 — Phase 2

Idiopathic Osteoporosis Research Study Groups: Romosozumab followed by denosumab

Idiopathic Osteoporosis Clinical Trial 2023: Denosumab Highlights & Side Effects. Trial Name: NCT04800367 — Phase 2

Denosumab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04800367 — Phase 2

~4 spots leftby Mar 2025

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.